ArticleBMC psychiatry2026
Clinical importance of the 5-Step Precision Medicine (5SPM) method in shared decision-making to choose the antipsychotic treatment for a patient with first-episode psychosis: a case report.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAdverse effects can disrupt early treatment in first-episode psychosis and precipitate discontinuation. We report the use of the five-step precision medicine (5SPM) method in personalised precision psychiatry to guide antipsychotic decision-making in a patient with first-episode psychosis. CASE PRESENTATION: A 26-year-old woman with regular tobacco and cannabis use was admitted to an acute psychiatric ward with persecutory delusions, behavioural dysregulation, anxiety and insomnia. Olanzapine (7.5 mg) was initiated and aripiprazole (20 mg) added to transition to aripiprazole monotherapy. Soon after aripiprazole introduction, she developed pain and cramps circumscribed to her arms, rejected treatment, and symptoms did not remit. A 5SPM-guided assessment, including pharmacogenetic testing and a structured review of pharmacokinetic interactions and environmental factors, provided a coherent basis to interpret an uncommon tolerability signal and to rationalise a change in antipsychotic strategy. Following shared decision-making, aripiprazole was withdrawn and olanzapine optimised; arm symptoms resolved within days, psychotic symptoms ceased, and she was discharged. At six months, she remained adherent to pharmacological treatment, which was eventually switched to long-acting injectable olanzapine following the patient's preference, had stopped cannabis and returned to work.
conclusionsIn this case, precision-guided shared decision-making was associated with treatment continuity in early psychosis by resolving an atypical adverse effect and improving clinical and functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.